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Abstract
Background: With the advent of next generation sequencing, tumor and germline
genomic testing are increasingly being used in the management of pediatric cancer
patients. Despite this increase in testing, many pediatric hematology–oncology (PHO)
providers are not confident interpreting or utilizing tumor or germline genomic results
to care for their patients.
Methods: We developed and delivered a needs assessment survey to PHO program
directors, attendings, and fellows in the United States to understand this deficiency,
gather data on existing cancer genomics educational initiatives, and query preferences
for creating a future curriculum.
Results: The survey includes 31 (41%) of 74 invited PHO program directors, 110
(11%) of 1032 invited attendings, and 79 fellows. The majority of attending physicians and fellows responding to the survey agree that understanding tumor (95%
attending physicians; 95% fellows) and germline (86% attending physicians; 94%
fellows) genomic information is essential for their practice. However, only 9 of 31
(29%) responding programs report that they have an existing cancer genomics curriculum. Most program directors indicated that the ideal genomics curriculum would
occur during the first year of fellowship and incorporate direct patient care, online
modules, and problem-based learning. Attending physicians and fellows identified
that addressing indications for ordering tumor and germline genomic testing, counseling about the risks and benefits of such testing, and interpreting and individualizing
clinical management based on tumor and germline results should be included in a
future curriculum.
Conclusion: The results of this study reveal a great need to develop a curriculum that
can be offered across PHO fellowship programs to expand knowledge in the area of
cancer genomics.
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IN T RO D U C T IO N

As clinical next generation sequencing (NGS) of pediatric tumors has become less costly and more rapid, there has been
an expansion in its use to streamline cancer diagnosis, refine
prognosis, and guide treatment decisions.1-3 Indeed, NGS is
increasingly being incorporated into the care of children with
cancer, including newly diagnosed patients as well as those
with relapsed/refractory disease.1 Despite this increase in
use, in one recent study only 35% of pediatric hematology–
oncology (PHO) providers felt confident interpreting, using,
and discussing tumor NGS test results with families.4 In another study, only 62% of pediatric oncologists felt confident
making treatment recommendations based on tumor NGS
information.5
Germline NGS is also increasingly being offered to
pediatric oncology patients to identify those with an underlying cancer predisposition. Germline results can guide
cancer treatment decisions and provide crucial information
about the risk to develop future cancers or non-oncologic
scale sequencing studies
manifestations.6-9 Recent large-
have revealed the presence of pathogenic or likely pathogenic germline variants associated with known cancer predisposition syndromes in at least 9–12% of children with
cancer,7-10 with this proportion likely to grow as new predisposition genes are identified.7-10 Nevertheless, only 33%
of PHO physicians at one institution were confident using
germline genetic findings for patient care, and only 37%
were comfortable discussing these results with patients and
families.5
Although the Accreditation Council for Graduate
Medical Education (ACGME) requires PHO fellows to
receive “structured educational instruction in the related
basic sciences,” which includes genetics,11 recent data
show that PHO physicians lack confidence in applying genetic information to patient care.4,5 This lack of confidence
may be due to limited education about cancer genomics
during fellowship training. As NGS becomes the standard-
of-care, it is essential that PHO physicians are competent in
understanding and using these results to care for their patients. Even so, there appears to be a significant knowledge
gap among PHO providers.
To explore the perspectives of PHO physicians surrounding education in tumor and germline genomics, we
completed a general and targeted needs assessment of PHO
fellowship program directors, attending physicians, and
fellows in the United States as part of the six steps of curriculum development.6 This assessment included identifying how PHO fellowship programs are currently carrying
out cancer genomics education, as well as what they believe to be the ideal approach to such education. The needs
identified through this study can be used to design a curriculum that will provide PHO fellows as well as faculty with
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the knowledge required to optimally incorporate tumor and
germline genomic information into the care of their patients with cancer.6

2
2.1
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M ETHODS

|

Participant recruitment

This study was approved by the Institutional Review Board
at St. Jude Children's Research Hospital. An invitation to
take part in this study was sent to potential participants via
email. The invitation included a link to the corresponding
online needs assessment survey.12 The first email invitation
was sent on 28 April 2020, and a reminder invitation was
sent 2 weeks later. The survey was open for 4 weeks. All
emails were sent, and responses were tracked using Active
Campaign.13

2.2 | PHO fellowship program
directors and fellows
The initial invitation to participate was sent to all 74 PHO
fellowship training programs in the United States. For 70
of these programs, the invitation was sent directly to the
program director for review and consideration of participation, as well as to the program coordinator so that it could
be forwarded to the PHO fellows at their respective training
programs. For four programs, the invitation was sent only to
the program coordinator because contact information for the
program director was not readily available. Email addresses
were obtained from the ACGME accreditation data system14
or from the Fellowship and Residency Electronic Interactive
Database (FREIDA).15 A link to the survey for fellows was
also posted on the American Society of Pediatric Hematology
Oncology online forum (ASPHO).

2.3

|

PHO attending physicians

The initial invitation email was also sent to 1103 PHO-
attending physicians. Seventy-two emails (6.5%) were returned as undeliverable, four physicians sent an automatic
reply with a new email address (0.3%), and three (0.3%)
unsubscribed from the initial email. Accounting for these
changes, the reminder invitation was sent to 1032 PHO-
attending physicians. Email addresses for attending physicians were extracted from the websites of PHO Divisions and
Departments associated with each of the 74 fellowship programs. When PHO-attending physician names, but not email
addresses, were displayed on the websites, we predicted
the email addresses according to their institutional email
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structure from other known email addresses for individuals
at the institution, as found through various online sources.

|

2.4

Surveys

The surveys used in this study were developed by the study
team, and the content was validated by seven clinical genomics experts (PHO physicians and genetic counselors) who
were not associated with the project and from institutions
other than St. Jude Children's Research Hospital. Content validity was established for 10 novel objective questions and 12
novel subjective questions.16,17 Although only one question
did not meet the previously defined validation criteria,16,17
four objective questions and nine subjective questions were
removed from the final survey to shorten the survey length.
It was considered that the benefit gained from the answers
to these 13 questions was not worth the risk of a reduced
response rate. The PHO attending physicians and fellows
survey included up to 20 questions, depending on how some
of the questions were answered. One of these questions was
optional. The PHO program director survey included up to
10 questions. Specifically, PHO fellowship directors at programs with an existing clinical genomics curriculum were
asked 10 questions, 9 of which were mandatory, while PHO
fellowship directors at programs without a clinical genomics
curriculum were asked 5 mandatory questions. All of the surveys can be found in the Supplemental Materials.

|

2.5

Data analysis

Basic descriptive statistics were used to analyze survey results. Fisher's exact test was used to compare the answers to
questions between the attendings and fellows. Bhapkar's test
was used to compare the answers to questions about tumor
and germline genomics. Two-
sided P-
values <0.05 were
considered significant. All statistical analyses were conducted using R version 4.0.2.
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3.1
3.1.1

R E S U LTS
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Program directors

|

Demographics and response rate

Thirty-one of 74 possible PHO fellowship programs (42%)
from 23 states and the District of Columbia completed the
survey (Table S1).
Among these 31 programs, only 9 (29%) reported having existing cancer genomics curricula, ranging from 0 to
36 months in length. Each of the programs with a curriculum

relied on local individuals with expertise in genetics and genomics such as geneticists, genetic counselors, oncologists,
and pathologists to teach some, if not all, of the curriculum
content. Eight program directors provided further information
about the structure of their curricula, with all eight (100%)
using in-person lectures, five (63%) including direct patient
care, and one (13%) incorporating problem-based learning.
All program directors were asked to identify the characteristics that they considered ideal for a future cancer genomics curriculum for PHO fellows. Twenty-two (71%) program
directors indicated the first year of the fellowship training
would be the best time to implement a cancer genomics curriculum. Several educational methods were elected as appropriate for inclusion, including direct patient care (25 program
directors, 81%), online modules (24 program directors, 77%),
problem-
based learning (20 program directors, 65%), recorded lectures viewed online (17 program directors, 55%),
assigned readings (16 program directors, 52%), and a mobile
phone application (5 program directors, 16%). In an optional
free response question, several program directors mentioned
the importance of flexibility in terms of scheduling lectures
and other activities, and incorporating multifaceted learning.

3.2
3.2.1

|

PHO attendings and fellows

|

Demographics and response rate

The survey was completed by 110 of 1032 of PHO attending
physicians (11%). These attending physicians represented
41 institutions from 26 states and the District of Columbia
(Table S1).
There are presumably 474 PHO fellows in the United
States at 74 distinct programs based on fellowship match data
from 2017 to 2019.18 Among these, 79 (17%) completed the
survey. Based on how the survey was completed, it is not possible to determine how many fellows actually received the
invitation to participate because the survey was anonymous
and the program directors and coordinators did not notify
the study team as to which PHO fellows they forwarded the
survey. The 79 PHO fellows who participated in this study
represent 31 PHO fellowship programs in 24 states and the
District of Columbia (Table S1).

3.2.2

|

Genomics curriculum relevance

PHO attendings and fellows report that genomics is very
relevant to their clinical practice. Specifically, 104 of 110
(95%) attendings and 75 of 79 (95%) fellows strongly
agreed or agreed that it was essential that they become
competent in ordering and interpreting tumor genetic testing, and 95 of 110 (86%) attendings and 74 of 79 (94%)
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For my clinical practice, it is essential to
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Strongly agree

Agree

PHO Aendings

PHO Fellows

For my clinical practice it is essential that I
become competent in ordering and
interpreting germline genetic testing

Disagree

Neutral

Strongly Disagree

F I G U R E 1 Relevance of cancer genomics to the practice of pediatric hematology oncology. PHO attendings and fellows were asked if they
felt it was essential to their practice to become competent in ordering and interpreting tumor (A) and germline (B) genetic testing. The proportions
of attendings and fellows responding to specific survey options are as shown.

fellows strongly agreed or agreed that it was essential that
they become competent in ordering and interpreting germline genetic testing (Figure 1). Two (2%) attending physicians did not agree that ordering and interpreting tumor
genetic testing was relevant to their practice; one attending
noted that there are already experts in genomics available
to guide this testing at their institution and the other indicated that he/she does not often order or interpret clinical
genomic testing for pediatric cancer patients. Similarly,
four (4%) attending physicians who did not agree that ordering and interpreting germline genetic testing was relevant to their practice indicated that there is a geneticist/
genetic counselor or other expert available to guide this
testing at their institution.

3.2.3

|

Local genomics expertise

Ninety-eight (89%) attending physicians and 66 (84%) fellows indicated that they have an individual such as an oncologist or molecular pathologist at their institution to consult
with prior to ordering tumor genetic testing. Similarly, 105
(95%) PHO attending physicians and 69 (87%) PHO fellows have access to a geneticist or genetic counselor with
whom they can consult prior to ordering germline genetic
testing.

3.2.4

|

Genomics curriculum preferences

When queried regarding the importance of specific topics for
inclusion in a cancer genomics curriculum, the topics indicated as “mandatory” by attendings and fellows included: (i)
identifying indications for ordering tumor genomic testing
(90% of attendings and 84% fellows); (ii) identifying indications for ordering germline genomic testing (87% attendings and 80% fellows); (iii) interpreting and individualizing
clinical management based upon tumor genomic results (79%
attendings and 75% fellows); (iv) interpreting and individualizing clinical management based upon germline genomic results (72% attendings and 73% fellows); (v) counseling on the
risks and benefits of tumor genomic testing (75% attendings
and 57% fellows); and (vi) counseling on the risks and benefits of germline genomic testing (69% attendings and 57%
fellows) (Figure 2 and Table S2). Notably, attendings from
institutions where there is ready access to hereditary cancer
expertise were significantly more likely to rate “Identifying
indications for ordering germline testing” as a mandatory
topic (71%) compared with attendings at institutions without
such expertise (40%, p = 0.028).
In a free response question, several attending physicians
indicated that ethical and financial considerations surrounding
genetic testing should also be included in the curriculum as
well as education on how to properly collect a family history.
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100%
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50%
40%
30%
20%
10%
0%

PHO Attendings PHO Fellows PHO Attendings PHO Fellows PHO Attendings PHO Fellows PHO Attendings PHO Fellows PHO Attendings PHO Fellows PHO Attendings PHO Fellows

Identifying indications
for ordering tumor
genetic testing

Identifying indications
for ordering germline
genetic testing

Mandatory

Counseling on the
risks and benefits of
ordering tumor
genetic testing

Counseling on the
risks and benefits of
ordering germline
genetic testing

Important but not mandatory

Interpreting and
individualizing
clinical management
based upon tumor
genetic results

Interpreting and
individualizing
clinical management
based upon germline
genetic results

Topic should not be included

F I G U R E 2 Importance of specific topics for inclusion in the ideal cancer genomics curriculum. PHO attendings and fellows were asked if
various topics should be included in the ideal cancer genomics curriculum. The proportions of attendings and fellows responding to specific survey
options are as shown.
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D IS C U SS ION

Although tumor and germline genomic testing are becoming
standard of care for pediatric cancer patients,1-3 many PHO
providers are not certain about how to interpret or use the
resulting information to care for their patients.4,5 This deficit could be due to a lack of formal educational initiatives
that focus on cancer genomic testing, analysis of genomic
data, and the clinical and ethical implications of test results.
It is essential that this deficit be addressed if providers are to
effectively and ethically incorporate genomic data into the
care of their pediatric cancer patients. To better understand
this deficit, we queried PHO program directors, attendings,
and fellows about their current educational initiatives in cancer genomics and explored the factors that they felt should
be included in a future curriculum. Collectively, 104 of 110
(95%) responding attendings and 75 of 79 (95%) responding
fellows report that understanding tumor genomic information is very relevant to their practice (Figure 1). Similarly,
95 of 110 (86%) attendings and 74 of 79 (94%) fellows felt
the same way about understanding germline genomic information (Figure 1). Nevertheless, 22 of 31 (71%) responding
programs do not yet have a formal cancer genomics curriculum for PHO fellows at their institution. Thus, there is a great
need to develop such a curriculum that can be offered across
PHO programs to expand knowledge in the area of cancer
genomics.
Successful development of educational curricula in other
fellowship programs has been achieved and may serve as a
framework for development of a genomics-focused curriculum for PHO fellows.19,20 A needs assessment performed

among pediatric emergency medicine fellowship directors
identified the need for and led to development of a national
patient safety curriculum for pediatric emergency medicine
fellows.19 This curriculum was successful in increasing fellows' knowledge of patient safety issues and heightening
awareness of safety issues and incorporation of safety strategies into clinical practice.19 Additionally, Reiss et al. reported incorporation of simulation-based curricula regarding
chemotherapy writing, bone marrow biopsy and intrathecal
chemotherapy administration, and patient-centered communication skills training in an adult Hematology–Oncology
fellowship program.20 This study found that the workshop-
based curriculum led to increased knowledge and comfort
of fellows with the elements of cancer care.20 Development
and incorporation of a genomics curriculum for PHO fellows
may similarly benefit trainees by increasing their knowledge,
comfort, and utilization of genomic information in clinical
practice.
It is interesting to note that attendings who have access
to individuals with hereditary cancer expertise were significantly more likely to rate “Identifying indications for ordering germline testing” as a mandatory topic (70.5%) for
inclusion in a cancer genomics curriculum compared with
those without such access (40%, p = 0.028). This may indicate that these attendings recognize the value of this service
and want to be involved in the process. By contrast, five attending physicians indicated that ordering and interpreting
the results of tumor or germline testing were not relevant,
as there already existed a genomics expert at their institution who was available to help guide and follow up on such
testing. It is important to recognize that not all institutions
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will have access to these experts. Due to the rapid increase
in genetic testing and limited number of genetic counseling training programs, there is currently a shortage of genetic counselors in the United States.21 While this shortage
is projected to reach equilibrium between 2024 and 2030,21
PHO is not a primary specialty among genetic counselors.22
According to the National Society of Genetic Counselors
2020 Professional Status Survey, only 1% of genetic counselors work in pediatric oncology and 0.5% in adult and pediatric hematology.22 Therefore it may be challenging to recruit
genetic counselors to work in the PHO setting. Based on this
information, it is even more essential that PHO providers are
educated in the area of germline genomics. Our data indicate
that the majority of PHO physicians see value in gaining personal knowledge of tumor and germline genomics and better
understanding how this information can be used to improve
patient care.
In our survey, the majority of participants reported that
identifying indications for ordering tumor and germline genetic testing, counseling on the risks and benefits of tumor
and germline genetic testing, and interpreting and individualizing clinical management based on tumor and germline
genetic results should be mandatory for inclusion in a future
cancer genomics curriculum. Curiously, more attending
physicians preferred mandatory inclusion (75%) of counseling on the risks and benefits of tumor genetic testing when
compared with the fellows (57%, p = 0.014). Counseling
is integral to obtaining consent for genetic testing of any
kind23-25 and should address key topics such as the types
of test results, the implications and management based on
results, and the potential for and protections against genetic
discrimination.25 The scope and limitations of the Genetic
Information Nondiscrimination Act (GINA)26 must be thoroughly discussed when germline testing is being offered.25
GINA is a law that was enacted in 2008 that prevents
certain health insurance companies and employers from
discriminating against individuals who have genetic conditions.25 Additionally, ethical considerations including the
familial implications of germline test results, discussion of
testing minors for adult-onset conditions, and potential for
incidental findings such as consanguinity or non-paternity
should be reviewed prior to initiation of germline testing.25
Counseling regarding tumor genetic testing should include
discussion of the potential to uncover variants that are
likely to be of germline origin. This discrepancy between
attending and fellow responses suggests that fellows require
further training to fully appreciate the nuances and ethical implications of the tumor and germline genetic testing
process.
Direct patient care (81%) was the most commonly selected
option for inclusion in an ideal clinical genomics curriculum.
Notably, of the 74 institutions currently offering a PHO fellowship, 46 also offer a Medical Genetics residency15 or a
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Genetic Counseling graduate program27 (Table S3). As medical genetics and genetic counselor training programs incorporate cancer predisposition education in their own curricula,
they could serve as an important resource when developing a
cancer genomics curriculum for PHO fellows. For example,
PHO fellows could rotate along with medical genetics residents or genetic counseling students as they complete this
component of their training.
With advancements in technology, creating a curriculum
that is flexible, multifaceted, comprehensive, and available
to every PHO fellowship program is possible. Today, distance and online learning are prevalent.28,29 The incorporation of technology in the classroom has only increased with
the COVID19 pandemic.28-30 Most PHO program directors
indicate that it would be best to deliver a cancer genomics
curriculum during the first year of fellowship, with online
modules and direct patient care as primary components. An
online module could include the other proposed learning
models such as problem-based learning, recorded lectures,
and discussion of assigned readings. There are many existing resources (Table 1) that can be utilized as a part of, or
in addition to, this curriculum. The use of distance learning
and recorded lectures allows for students to learn from the
most qualified individuals who may not be necessarily available to give in-person lectures.28 Even at smaller institutions
without local expertise in cancer genomics, patients could
still receive consultation from experts in cancer genomics
through the use of telehealth, as has been done in other specialties.31-33 Another point of access to expert knowledge in
cancer genomics could be online information sharing platforms that allow subject matter experts to widely disseminate
their expertise in a more rapid manner than through traditional peer-reviewed publications.34 This type of platform
has recently been used to disseminate expert knowledge
surrounding how to care for oncology patients during the
COVID19 pandemic.34
Despite its strengths, this study also has some limitations.
First, we were not able to determine the true response rate
among PHO fellows because we do not know how many fellows received the invitation to participate. To optimize the response rate, we kept the survey short and focused. As a result,
only limited information was collected. Further, information
could have been gathered regarding current strategies for how
best to introduce PHO fellows to tumor and germline genomics. Similarly, it would have been interesting to know which
programs had existing Developmental Therapeutics (DT) initiatives which rely heavily on generation and understanding
of tumor genomic information. Accordingly, it is possible
that PHO providers or fellows from institutions with DT initiatives might have answered questions differently than those
from institutions without such initiatives. Last, only 10% of
PHO attendings and 42% of PHO fellowship programs responded to this survey. Despite these incomplete response
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Existing genomics resources.

Resource

Type

Content

ASCO Genetics Toolkit
https://www.asco.org/practice-polic
y/cancer-care-initiatives/genet
ics-toolkit

CME courses & Tumor Boards

Background of Cancer Predisposition Syndromes;
Testing Strategies, Risk Assessments, and Ethical
Considerations

ASCP Training Residents in
Genomics
https://www.pathologylearning.org/
trig/courses-workshops

Working Group

General Genetics Education

National Human Genome Research
Institute
https://www.genome.gov/For-Healt
h-Professionals/Provider-Genom
ics-Education-Resources

Readings, Webinars, Curriculum

General Genomics Education

City of Hope Cancer Genomics
Education Program
https://www.cityofhope.org/educa
tion/health-professional-educa
tion/cancer-genomics-educa
tion-program

Online Course

Hereditary Cancer Education

MIPOGG
https://mipogg.com/

App

Cancer Predisposition Syndromes, When to refer to
genetics

ASH Genomics resources
https://www.hematology.org/educa
tion/educational-programs/
genom

Online Modules

Basic & disease-specific hematology and oncology
genomics

rates, these values are comparable to those observed in similar studies.27-30,35,36 To the best of our knowledge, this effort,
which used the first three steps of curriculum development,6
was the first to assess PHO program directors, attendings,
and fellows for their interest in and needs for a cancer genomics curriculum.
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CO NC LUS ION

This study reveals that the majority of PHO attendings and
fellows recognize the importance of clinical cancer genomics
and express a need for developing a curriculum to expand
knowledge in the areas of tumor and germline testing, including how and when to order specific tests and how to interpret
and act upon the results. Further efforts are needed to develop
such a cancer genomics curriculum so that PHO providers
can capitalize on the full potential of precision medicine to
improve the diagnosis and management of children with
cancer.
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